{
    "organizations": [],
    "uuid": "c6395c14c2fd0733303bcc2d0504363a78ec87b3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-immutep-ltd-enters-into-clinical-t/brief-immutep-ltd-enters-into-clinical-trial-collaboration-with-merck-co-idUSFWN1QT03F",
    "ord_in_thread": 0,
    "title": "BRIEF-Immutep Ltd Enters Into Clinical Trial Collaboration With Merck & Co",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 12 (Reuters) - Immutep Ltd:\n* ENTERED INTO A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK & CO., INC\n* DEAL TO EVALUATE COMBINATION OF IMMUTEP’S IMMUNOTHERAPY PRODUCT CANDIDATE WITH MSD’S ANTI-PD-1 THERAPY KEYTRUDA IN A NEW CLINICAL TRIAL Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-12T03:14:00.000+02:00",
    "crawled": "2018-03-12T03:33:21.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "immutep",
        "ltd",
        "entered",
        "clinical",
        "trial",
        "collaboration",
        "supply",
        "agreement",
        "merck",
        "inc",
        "deal",
        "evaluate",
        "combination",
        "immutep",
        "immunotherapy",
        "product",
        "candidate",
        "msd",
        "therapy",
        "keytruda",
        "new",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}